Related Experiment Video
Updated: May 5, 2026
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers
Jiexin Zhang1, Guanbin Gao2, Meng He1
1Hubei Key Laboratory of Nanomedicine for Neurodegenerative Diseases, School of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, 122 Luoshi Road, Wuhan, 430070, PR China.
Insights
Semaglutide shows significant cardiovascular benefits for patients with heart failure and diabetic cardiomyopathy. Further research is needed to optimize its use and address potential side effects like gastrointestinal issues.
Area of Science:
- Cardiology and Endocrinology
- Pharmacological research on GLP-1 receptor agonists
Background:
- Cardiovascular disease (CVD) is the leading cause of mortality globally.
- Heart failure with preserved ejection fraction, diabetic cardiomyopathy, and atherosclerotic cardiomyopathy are key risk factors.
- Semaglutide, a GLP-1 receptor agonist, shows promise for CVD treatment.
Purpose of the Study:
- To review evidence on semaglutide's cardiovascular outcomes and mechanisms since 2016.
- To explore emerging therapeutic frontiers for semaglutide in CVD management.
- To utilize bibliometric analysis for mapping research trends.
Main Methods:
- Bibliometric analysis including burst detection and cluster timeline analysis.
- Synthesis of accumulating evidence on semaglutide's cardiovascular effects.
- Review of mechanistic insights and clinical trial data.
Main Results:
- Semaglutide demonstrates cardiovascular benefits, improving insulin resistance, inflammation, and atherosclerosis.
- Novel associations with ferroptosis inhibition are identified.
- Clinical data suggests a need for precision-based regimen design for diverse patient subgroups.
Conclusions:
- Semaglutide is a promising therapeutic candidate for cardiovascular disease.
- Further validation is required for potential lean mass reduction and gastrointestinal tolerability.
- This review aims to expand semaglutide's clinical application and identify new therapeutic avenues.
Abstract:
Cardiovascular disease (CVD) remains the leading cause of global mortality, with pathophysiological alterations such as heart failure with preserved ejection fraction, diabetic cardiomyopathy, and atherosclerotic cardiomyopathy representing major risk factors. Semaglutide, a novel long-acting glucagon-like peptide-1 receptor agonist, has demonstrated substantial efficacy in glycemic control and weight reduction. Since 2016, accumulating evidence has highlighted its promising cardiovascular benefits, establishing semaglutide as a strong therapeutic candidate for CVD. This review synthesizes evidence since 2016 to elucidate semaglutide's cardiovascular outcomes, underlying mechanisms, and emerging frontiers, employing bibliometric analytical approaches such as burst detection mapping and cluster timeline analysis of references and keywords. Research on semaglutide in CVD has advanced rapidly, with mechanistic insights including improvements in insulin resistance, anti-inflammatory activity, and anti-atherosclerotic effects, as well as novel associations with ferroptosis inhibition. Clinical evidence across diverse patient subgroups indicates that future implementation will require precision-based regimen design. Moreover, although oral semaglutide alleviates injection-related discomfort, its gastrointestinal tolerability remains a concern. Furthermore, the potential reduction in lean mass requires further validation. Overall, this review aims to broaden the clinical application of semaglutide and highlight novel therapeutic avenues for patients with cardiovascular disease.
Related Concept Videos
01:11Clinical Trials: Overview
01:29Pharmacogenomics: Identification of New Drug Targets
01:21Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...